← Back to Search

Whole Blood Transfusion for Trauma Patients

Phase 3
Waitlist Available
Research Sponsored by Loma Linda University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours post ed admission
Awards & highlights

Summary

This trial is looking at whether or not adult male patients who are brought to the emergency department as Level A trauma activations and are receiving emergency blood transfusion benefit from receiving more blood.

Eligible Conditions
  • Acute Blood Loss Anemia
  • Hemorrhagic Shock
  • Traumatic Brain Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours post ed admission
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours post ed admission for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
pRBC equivalents transfused
Secondary outcome measures
Mortality

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Low Titer O+ Whole BloodExperimental Treatment1 Intervention
Low Titer O+ Whole blood provided to Level A trauma patients
Group II: Component TherapyActive Control1 Intervention
Component Therapy of O+ pRBC and FFP dispatched to trauma bay for level A traumas
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Routine labs
2022
Completed Phase 3
~210

Find a Location

Who is running the clinical trial?

Loma Linda UniversityLead Sponsor
308 Previous Clinical Trials
260,919 Total Patients Enrolled
1 Trials studying Anemia
299 Patients Enrolled for Anemia

Media Library

Component Therapy Clinical Trial Eligibility Overview. Trial Name: NCT05081063 — Phase 3
Anemia Research Study Groups: Low Titer O+ Whole Blood, Component Therapy
Anemia Clinical Trial 2023: Component Therapy Highlights & Side Effects. Trial Name: NCT05081063 — Phase 3
Component Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05081063 — Phase 3
~60 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top